Q2 Earnings Estimate for RYTM Issued By Leerink Partnrs

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) - Equities research analysts at Leerink Partnrs issued their Q2 2025 EPS estimates for shares of Rhythm Pharmaceuticals in a research note issued to investors on Monday, July 7th. Leerink Partnrs analyst F. Khurshid forecasts that the company will earn ($0.87) per share for the quarter. Leerink Partnrs currently has a "Strong-Buy" rating on the stock. The consensus estimate for Rhythm Pharmaceuticals' current full-year earnings is ($4.32) per share. Leerink Partnrs also issued estimates for Rhythm Pharmaceuticals' Q3 2025 earnings at ($0.90) EPS, Q4 2025 earnings at ($0.92) EPS, FY2025 earnings at ($3.49) EPS, FY2026 earnings at ($2.86) EPS, FY2027 earnings at ($2.07) EPS, FY2028 earnings at ($0.42) EPS and FY2029 earnings at $1.28 EPS.

Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.12). The firm had revenue of $37.72 million for the quarter, compared to analyst estimates of $40.43 million. Rhythm Pharmaceuticals had a negative net margin of 123.26% and a negative return on equity of 739.62%. The company's quarterly revenue was up 25.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($2.35) EPS.

A number of other equities analysts also recently commented on the stock. Oppenheimer lifted their price objective on shares of Rhythm Pharmaceuticals from $76.00 to $110.00 and gave the stock an "outperform" rating in a report on Thursday. Wells Fargo & Company lifted their price target on shares of Rhythm Pharmaceuticals from $91.00 to $129.00 and gave the company an "overweight" rating in a report on Thursday. HC Wainwright reaffirmed a "buy" rating and set a $80.00 price objective (up previously from $70.00) on shares of Rhythm Pharmaceuticals in a research report on Tuesday, April 8th. Morgan Stanley set a $95.00 target price on shares of Rhythm Pharmaceuticals and gave the stock an "overweight" rating in a report on Wednesday. Finally, Stifel Nicolaus upped their target price on Rhythm Pharmaceuticals from $78.00 to $94.00 and gave the company a "buy" rating in a report on Thursday, May 29th. Fourteen analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $91.00.

Rhythm Pharmaceuticals Stock Performance

Shares of NASDAQ RYTM traded down $2.34 during trading on Thursday, reaching $86.70. The stock had a trading volume of 1,105,173 shares, compared to its average volume of 588,517. The stock has a market cap of $5.52 billion, a PE ratio of -30.85 and a beta of 2.26. Rhythm Pharmaceuticals has a one year low of $40.61 and a one year high of $94.80. The firm's 50 day moving average price is $64.34 and its two-hundred day moving average price is $59.31.

Insider Buying and Selling at Rhythm Pharmaceuticals

In other news, insider Joseph Shulman sold 7,969 shares of the firm's stock in a transaction on Wednesday, July 9th. The stock was sold at an average price of $77.78, for a total transaction of $619,828.82. Following the transaction, the insider directly owned 8,509 shares of the company's stock, valued at approximately $661,830.02. This trade represents a 48.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Pamela J. Cramer sold 15,572 shares of Rhythm Pharmaceuticals stock in a transaction dated Wednesday, July 9th. The shares were sold at an average price of $77.13, for a total transaction of $1,201,068.36. Following the sale, the insider owned 19,209 shares in the company, valued at approximately $1,481,590.17. This represents a 44.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 93,673 shares of company stock valued at $7,118,510. 6.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Rhythm Pharmaceuticals

Several large investors have recently bought and sold shares of the stock. BI Asset Management Fondsmaeglerselskab A S bought a new position in shares of Rhythm Pharmaceuticals in the first quarter valued at approximately $34,000. SBI Securities Co. Ltd. acquired a new stake in Rhythm Pharmaceuticals in the fourth quarter worth approximately $37,000. State of Wyoming bought a new position in Rhythm Pharmaceuticals during the 4th quarter valued at $61,000. GF Fund Management CO. LTD. acquired a new position in shares of Rhythm Pharmaceuticals during the 4th quarter valued at $72,000. Finally, CWM LLC increased its position in shares of Rhythm Pharmaceuticals by 92.3% during the 1st quarter. CWM LLC now owns 2,584 shares of the company's stock valued at $137,000 after purchasing an additional 1,240 shares during the period.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.